Stay updated on Ociperlimab and Tislelizumab vs Pembrolizumab in Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the Ociperlimab and Tislelizumab vs Pembrolizumab in Lung Cancer Clinical Trial page.

Latest updates to the Ociperlimab and Tislelizumab vs Pembrolizumab in Lung Cancer Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedVersion 3.5.2 adds comprehensive study data sections (Adverse Events, Outcome Measures, Baseline Characteristics, Participant Flow, IPDSharing, Eligibility, Arms and Interventions, Study Design, Study Description, Study Status, Study Identification, Recruitment Status). It updates the revision timeline to reflect the new changes (Revision: v3.5.2, dated 2026-03-25).SummaryDifference2%

- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedThe history now shows 'Results Submitted' replacing 'No Results Posted'. The entry updates the record to indicate that study results have been submitted.SummaryDifference0.1%

- Check41 days agoChange DetectedSite revision updated to v3.5.0, replacing the prior v3.4.3.SummaryDifference0.1%

- Check48 days agoChange DetectedRevision label updated to v3.4.3, replacing the previous v3.4.2.SummaryDifference0.1%

- Check76 days agoChange DetectedA new revision entry (v3.4.2) was added to the history, and earlier items including a government funding notice and revision v3.4.1 were removed.SummaryDifference0.6%

- Check83 days agoChange DetectedAdded a government funding/operating status notice and updated the revision metadata from v3.4.0 to v3.4.1.SummaryDifference0.6%

Stay in the know with updates to Ociperlimab and Tislelizumab vs Pembrolizumab in Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ociperlimab and Tislelizumab vs Pembrolizumab in Lung Cancer Clinical Trial page.